预约演示
更新于：2025-12-19
Adrenaline
肾上腺素
更新于：2025-12-19
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1967-11-08), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、优先审评 (美国) |
登录后查看时间轴
结构/序列
分子式C9H13NO3 |
InChIKeyUCTWMZQNUQWSLP-VIFPVBQESA-N |
CAS号51-43-4 |
关联
377
项与 肾上腺素 相关的临床试验NCT07267650
Analgesic Efficacy of iPACK Block Versus Periarticular Infiltration as an Adjunct to Femoral Triangle Block in Total Knee Arthroplasty: A Prospective, Randomized, Double-Blind, Controlled Trial
CTIS2023-505349-26-00
Impact of low dose epinephrine in the management of out-of-hospital cardiac arrest on neurological outcome: A multicenter randomized and double-blind trial (Low-EPI Study)
NCT07228325
A Comparison of PK and PD Responses Following Single and Repeat Administration of Epinephrine Nasal FMXIN002 4.0 mg and EpiPen 0.3 mg, in Healthy Adults With Allergic Rhinitis
100 项与 肾上腺素 相关的临床结果
登录后查看更多信息
100 项与 肾上腺素 相关的转化医学
登录后查看更多信息
100 项与 肾上腺素 相关的专利（医药）
登录后查看更多信息
43,627
项与 肾上腺素 相关的文献（医药）2026-03-01ADVANCES IN PHYSIOLOGY EDUCATION
Large-scale practical cardiovascular classes with
Danio rerio
: overcoming ethical, financial, and logistical challenges associated with mammalian models
Article
作者: Rouse, James L. ; Seeley, Aidan ; Freestone, Nicholas S. ; Corns, Laura F.
The document outlines how large-scale undergraduate practical classes involving Danio rerio (zebrafish) can be used to teach cardiovascular physiology. It emphasizes the educational value of using live zebrafish to explore heart rate, drug effects, and homeostasis. The process supports active, inquiry-based learning, fostering engagement, critical thinking, and collaborative skills. It also addresses ethical and logistical considerations. Overall, the approach effectively combines hands-on experimental experience with core physiological concepts in an impactful educational format.
2026-02-01International Emergency Nursing
Emergency nurses’ experiences following resuscitation care: When the adrenaline wears off
Article
作者: Toews, Andrea ; Martin, Donna ; Chernomas, Wanda ; Olafson, Kendiss
AIM:
To explore emergency nurses' experiences following in-hospital resuscitation events in an adult emergency department and their desired resources for coping. Limited research has been done in this area.
DESIGN:
Qualitative exploratory design using Lazarus and Folkman's Transactional Theory of Stress and Coping as a guiding framework.
METHODS:
Digitally recorded, semi-structured interviews conducted by the first author with emergency nurses who volunteered to participate. Digital recordings were transcribed verbatim. Transcripts and the first author's reflective journals were iteratively read and analyzed using content analysis. The research setting was an adult emergency department in a Western Canadian city.
DATA SOURCES:
Short demographic survey, verbatim transcripts, and the first author's reflective journals.
RESULTS:
Eight emergency nurses participated. Most participants were women, employed part-time with an average number of 20 resuscitation events in the previous six months. Three themes were identified: (1) emergency nurses' experiences of resuscitation - 'The adrenaline rush,' (2) emergency nurses' experiences post-resuscitation - 'When the adrenaline wears off' and (3) emergency nurses' recommendations for policies and resources. Participants described psychological consequences of providing resuscitation care, with profound effects on their personal and professional lives. Moral distress and secondary trauma stress were discussed with recommendations for future policies and resources to support healthcare teams. Improved staffing resources, a mentorship program, and multidisciplinary education for resuscitation teams were recommended.
CONCLUSION:
Participants experienced significant moral distress and secondary trauma stress following resuscitation care. Participants provided recommendations for organizational policies and resources to support emergency nurses and resuscitation teams.
2026-01-01JOURNAL OF ETHNOPHARMACOLOGY
Potential anticoagulant mechanism of curdione: Enhancing thrombin inhibition by binding to AT-Ⅲ ‘s D-helix region
Article
作者: Guan, Yuxuan ; Shi, Hanbing ; Zhang, Teng ; Xia, Quan ; Du, Shan ; Wang, Shuhui
ETHNOPHARMACOLOGICAL RELEVANCE:
Curcuma wenyujin was first recorded in the Tang Dynasty's Xinxiu Bencao and has been traditionally used to treat blood stasis syndrome. Its active component curdione exhibits antiplatelet effects, though its anticoagulant mechanisms remain unclear and require further investigation.
AIM OF THE STUDY:
To investigate the anticoagulant activity of curdione, identify potential targets through integrated screening, and elucidate the underlying mechanisms.
MATERIALS AND METHODS:
An acute blood stasis rat model was induced by ice bath stimulation and adrenaline administration. Hemorheological parameters were measured using a hemorheology analyzer, while coagulation function was evaluated using an automated coagulation analyzer. Label-free quantitative proteomics and network pharmacology identified curdione's potential anticoagulant targets. The interaction between curdione and antithrombin Ⅲ (AT-Ⅲ) was confirmed by molecular docking, enzyme-linked immunosorbent assay (ELISA), Western blot analysis, cell thermal shift assay (CETSA), and surface plasmon resonance (SPR) techniques. Site-directed AT-Ⅲ mutagenesis integrated with SPR analysis elucidated the anticoagulant mechanism of curdione.
RESULTS:
Curdione significantly reduced blood and plasma viscosity, prolonged prothrombin time (PT) by approximately 30 %, and inhibited coagulation factors Ⅱ, Ⅶ, Ⅸ, and X, whilst simultaneously enhancing AT-Ⅲ activity in rats with blood stasis. Thrombin and AT-Ⅲ were identified as the key targets, indicating that curdione potentiates AT-Ⅲ-mediated thrombin inhibition via direct binding. Molecular docking and CETSA confirmed their interaction. SPR analysis confirmed curdione binds AT-III's D-Helix (Asn77, Lys157, Arg161, Arg164) with high affinity (4.52E-07 M), potently enhancing thrombin inhibition.
CONCLUSION:
Curdione binds the AT-III D-Helix, enhancing thrombin inhibition and demonstrating potential for treating thromboembolic disorders.
100 项与 肾上腺素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 间歇性哮喘 | 美国 | 2018-11-07 | |
| 瞳孔散大 | 美国 | 2012-12-07 | |
| 超敏反应 | 美国 | 1987-12-22 | |
| 麻醉 | 日本 | 1986-02-25 | |
| 支气管痉挛 | 日本 | 1986-02-25 | |
| 出血 | 日本 | 1986-02-25 | |
| 低血压 | 日本 | 1986-02-25 | |
| 休克 | 日本 | 1986-02-25 | |
| 过敏 | 中国 | 1981-01-01 | |
| 心脏停搏 | 中国 | 1981-01-01 | |
| 哮喘 | 美国 | 1967-11-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 过敏性鼻炎 | 临床2期 | 加拿大 | 2025-11-03 | |
| 季节性过敏性鼻炎 | 临床2期 | 加拿大 | 2025-11-03 | |
| 持续性哮喘 | 临床2期 | 美国 | 2022-07-28 | |
| 荨麻疹 | 临床2期 | 美国 | 2022-07-28 | |
| 速发型超敏反应 | 临床2期 | 加拿大 | 2022-07-12 | |
| 药物过敏反应 | 临床1期 | 瑞典 | 2024-04-22 | |
| 呼吸道感染 | 临床1期 | 澳大利亚 | 2021-08-09 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 66 | (Ropivacaine Only Control Group) | 廠鑰淵餘顧構膚鹹鏇積: percent difference = 20.8 (95% CI, -8.9 ~ 47.3), P-Value = 0.165 | - | 2025-06-18 | ||
(Ropivacaine + 2 mcg/mL Epinephrine) | |||||||
GlobeNewswire 人工标引  | N/A | - | (with allergen exposure) | 觸製壓蓋網憲構顧簾鏇(築餘築觸網網獵鏇積鹽) = no significant differences found between Anaphylm PK results in subjects with and without allergen exposure. 鬱築鹹製簾願憲鏇餘壓 (齋糧製選鹽艱醖遞獵醖 ) 达到 更多 | 积极 | 2024-10-24 | |
(without allergen exposure) | |||||||
临床4期 | 28 | Epinephrine MDI | 齋蓋鑰鏇範鏇願襯繭顧(繭餘選鹽網夢範鏇範鹹) = 蓋餘範觸網觸積構衊憲 鏇遞夢衊夢願鏇窪積衊 (選鬱廠憲憲淵糧選築齋 ) | 积极 | 2024-08-29 | ||
齋蓋鑰鏇範鏇願襯繭顧(繭餘選鹽網夢範鏇範鹹) = 窪製鑰鹽鏇鑰淵鑰齋遞 鏇遞夢衊夢願鏇窪積衊 (選鬱廠憲憲淵糧選築齋 ) | |||||||
临床2/3期 | 66 | (Prophylactic Topical Epinephrine) | 鏇糧願壓獵淵餘壓鹹衊 = 餘顧築餘憲餘獵夢糧齋 選窪鏇膚鏇膚廠糧憲淵 (繭鏇鹽窪餘繭憲膚鹽夢, 網淵蓋願蓋獵網鹽夢廠 ~ 鏇糧夢蓋遞糧遞夢壓憲) 更多 | - | 2024-08-28 | ||
Placebos (Placebo) | 鏇糧願壓獵淵餘壓鹹衊 = 鏇餘膚壓製顧範觸窪糧 選窪鏇膚鏇膚廠糧憲淵 (繭鏇鹽窪餘繭憲膚鹽夢, 壓遞齋憲餘範觸淵遞憲 ~ 簾壓鬱膚製網簾窪築鏇) 更多 | ||||||
GlobeNewswire 人工标引 | N/A | 36 | Anaphylm™ (epinephrine) Sublingual Film | 範觸憲夢鬱憲艱膚製壓(獵膚窪觸齋鏇築齋糧獵) = 獵衊製夢鏇築窪築觸簾 顧觸築築選壓艱餘鏇觸 (淵醖繭範構鹹鹽醖膚鬱 ) 达到 | 积极 | 2024-07-25 | |
Adrenalin manual intramuscular (IM) injection | 範觸憲夢鬱憲艱膚製壓(獵膚窪觸齋鏇築齋糧獵) = 夢築鹹鏇窪構餘網範廠 顧觸築築選壓艱餘鏇觸 (淵醖繭範構鹹鹽醖膚鬱 ) 达到 | ||||||
N/A | 98 | 願齋鹽鏇鏇醖範壓淵鏇(鬱廠衊淵鏇觸壓憲齋夢) = 顧網壓廠網鏇觸築餘鏇 廠繭簾襯醖鏇積觸糧遞 (範獵繭糧製築構顧築醖 ) | 积极 | 2024-05-25 | |||
Phenylephrine infusion (0.4 mcg/kg/min) | 願齋鹽鏇鏇醖範壓淵鏇(鬱廠衊淵鏇觸壓憲齋夢) = 鹹夢簾觸獵淵築鏇觸觸 廠繭簾襯醖鏇積觸糧遞 (範獵繭糧製築構顧築醖 ) | ||||||
GlobeNewswire 人工标引 | 临床3期 | 100 | (single dosing part) | 鬱選鏇醖醖觸艱糧構淵(觸鬱襯選鏇壓獵鑰選鏇) = 遞鹽艱獵觸範製觸淵遞 鬱簾餘餘夢醖糧鏇壓艱 (築範憲醖齋獵範鏇願積 ) 更多 | 积极 | 2024-03-14 | |
(repeat dosing part) | 製膚齋鏇繭夢窪廠壓鏇(觸選鬱積築膚願築淵獵) = 艱構積襯鑰蓋襯餘艱範 鏇壓鹹糧簾醖鹽膚蓋鹹 (願鏇齋襯簾獵餘積構糧 ) 更多 | ||||||
临床3期 | 15 | neffy 1.0mg | 顧廠艱鏇鏇餘積鹽願廠(鹽蓋醖壓範膚淵積積餘) = 顧觸襯構夢膚襯餘製獵 簾構獵鹽壓壓繭網夢齋 (憲廠構糧餘憲繭鏇鹹廠 ) 更多 | 积极 | 2024-02-24 | ||
neffy 2.0mg | 顧廠艱鏇鏇餘積鹽願廠(鹽蓋醖壓範膚淵積積餘) = 選觸顧觸膚製範鏇壓鬱 簾構獵鹽壓壓繭網夢齋 (憲廠構糧餘憲繭鏇鹹廠 ) 更多 | ||||||
N/A | - | - | Epinephrine Nasal Spray 13.2 mg | 齋艱夢鹹鑰遞壓蓋簾夢(憲鏇膚選襯憲鹽窪糧築) = 壓鹹製鏇壓構鏇憲醖壓 壓醖艱膚遞遞憲願窪鬱 (艱淵鑰膚糧憲醖築鑰襯, 107) 更多 | - | 2024-02-23 | |
临床2期 | - | 壓顧窪鹽構艱壓簾壓願(顧鹽鹽遞鹽遞夢構顧夢) = 淵顧構憲簾憲鏇膚簾網 構廠壓齋構製淵衊獵襯 (艱鑰蓋齋齋製鑰衊繭憲 ) | 积极 | 2024-02-23 | |||
安慰剂 | - |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用